Anticorps Recombinant de lapin anti-PCSK9

PCSK9 Recombinant Antibody for WB, IF/ICC, FC (Intra), ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

WB, IF/ICC, FC (Intra), ELISA

Conjugaison

Non conjugué

CloneNo.

241395G1

N° de cat : 84172-4-RR

Synonymes

241395G1, EC:3.4.21.-, FH3, HCHOLA3, LDLCQ1

---

Galerie de données de validation

• 

  WB analysis of HepG2 using 84172-4-RR

  HepG2 cells were subjected to SDS PAGE followed by western blot with 84172-4-RR (PCSK9 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  IF Staining of HepG2 using 84172-4-RR

  Immunofluorescent analysis of (4% PFA) fixed HepG2 cells using PCSK9 antibody (84172-4-RR, Clone: 241395G1 ) at dilution of 1:400 and CoraLite®488-Conjugated Goat Anti-Rabbit IgG(H+L) (SA00013-2), CL594-Phalloidin (red).

• 

  FC experiment of HeLa using 84172-4-RR

  1x10^6 HeLa cells were intracellularly stained with 0.25 ug PCSK9 Recombinant antibody (84172-4-RR, Clone:241395G1) and CoraLite®488-Conjugated Goat Anti-Rabbit IgG(H+L) (SA00013-2)(red), or 0.25 ug Rabbit IgG Isotype Control RecAb (98136-1-RR, Clone: 240953C9) (blue). Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).

• 

  Affinity and Kinetic Characterization of 84172-4-RR

  Biolayer interferometry (BLl) kinetic assays of 84172-4-RR against Human PCSK9 were performed. The affinity constant is 0.80 nM.

---

Applications testées

• Résultats positifs en WB: cellules HepG2,
• Résultats positifs en IF/ICC: cellules HepG2,
• Résultats positifs en FC (Intra): cellules HeLa,

Dilution recommandée

• Western Blot (WB): WB : 1:500-1:2000
• Immunofluorescence (IF)/ICC: IF/ICC : 1:200-1:800
• Flow Cytometry (FC) (INTRA): FC (INTRA) : 0.25 ug per 10^6 cells in a 100 µl suspension

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Informations sur le produit

84172-4-RR cible PCSK9 dans les applications de WB, IF/ICC, FC (Intra), ELISA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Hôte / Isotype: Lapin / IgG
• Clonalité: Recombinant
• Type: Anticorps
• Immunogène: Protéine recombinante
• Nom complet: proprotein convertase subtilisin/kexin type 9
• Masse moléculaire calculée: 74 kDa
• Poids moléculaire observé: 72-78 kDa, 62 kDa
• Numéro d’acquisition GenBank: NM_174936.4
• Symbole du gène: PCSK9
• Identification du gène (NCBI): 255738
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par protéine A
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial protein governing the circulating levels of low density lipoprotein-cholesterol (LDL-C), by virtue of its pivotal role in the degradation of the LDL receptor (LDLR). PCSK9 is expressed in the kidney and lung. It is synthesized as a 72 kDa immature precursor that undergoes autocatalytic cleavage in the endoplasmic reticulum to generate a 63 kDa mature protein. The cleaved N-terminal fragment remains associated with the mature protein and is necessary for its secretion, allowing it to circulate in the blood. The ability of PCSK9 to regulate a diverse group of cell-surface proteins hinted that it might also be able to influence additional membrane proteins that are important in anti-tumour immune responses. Targeting PCSK9 to treat cancer is also attractive because two neutralizing antibodies against it, evolocumab and alirocumab, have already been approved for human clinical use to lower cholesterol levels. (PMID: 30522786, PMID: 22493497)

{{ptg:RelatedPrimaryAntibodies}}